Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 3, 2009, Pages 575-583

  Robey, Robert W ^a,c   Obrzut, Tomasz ^a   Shukla, Suneet ^a   Polgar, Orsolya ^a   MacAlou, Sira ^b   Bahr, Julian C ^a   Di Pietro, Attilio ^b   Ambudkar, Suresh V ^a   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITÉ DE LYON   (France)

^c Bldg 10 ^*  (United States)

Author keywords

ABCG2; Becatecarin; Drug resistance; Rebecamycin derivative; Topoisomerase inhibitor

Indexed keywords

1,11 DICHLORO 6 (2 DIETHYLAMINOETHYL) 12,13 DIHYDRO 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 (4 O METHYLGLUCOSIDE); 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADENOSINE TRIPHOSPHATASE; BECATECARIN; BREAST CANCER RESISTANCE PROTEIN; DNA TOPOISOMERASE INHIBITOR; FUMITREMORGIN C; MITOXANTRONE; PHEOPHORBIDE; PHEOPHORBIDE A; PRAZOSIN; REBECCAMYCIN; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOMA CELL; CELL STRAIN; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG TRANSPORT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADENOSINE TRIPHOSPHATASES; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; AZIDES; BIOLOGICAL TRANSPORT; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCENCE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSIDES; HUMANS; IMMUNOBLOTTING; IODINE RADIOISOTOPES; LUNG NEOPLASMS; NEOPLASM PROTEINS; PRAZOSIN;

EID: 67349103361     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0908-2     Document Type: Article

References (37)

1. A Dowlati CL Hoppel ST Ingalls S Majka X Li N Sedransk T Spiro SL Gerson P Ivy SC Remick 2001 Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days J Clin Oncol 19 2309 2318 (Pubitemid 32372326)
2. J Merchant K Tutsch A Dresen R Arzoomanian D Alberti C Feierabend K Binger R Marnoccha J Thomas J Cleary G Wilding 2002 Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats Clin Cancer Res 8 2193 2201 (Pubitemid 34753590)
3. HJ Burstein B Overmoyer R Gelman P Silverman J Savoie K Clarke L Dumadag J Younger P Ivy EP Winer 2007 Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules Invest New Drugs 25 161 164 (Pubitemid 46020875)
4. M Hussain U Vaishampayan LK Heilbrun V Jain PM LoRusso P Ivy L Flaherty 2003 A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer Invest New Drugs 21 465 471 (Pubitemid 38124987)
5. S Goel S Wadler A Hoffman F Volterra C Baker E Nazario P Ivy A Silverman S Mani 2003 A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer Invest New Drugs 21 103 107 (Pubitemid 36628490)
6. AD Ricart LA Hammond JG Kuhn CH Takimoto A Goetz B Forouzesh L Forero JL Ochoa-Bayona K Berg AW Tolcher EK Rowinsky 2005 Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors Clin Cancer Res 11 8728 8736 (Pubitemid 43005923)
7. AM Langevin M Bernstein JG Kuhn SM Blaney P Ivy J Sun Z Chen PC Adamson 2008 A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study Pediatr Blood Cancer 50 577 580 (Pubitemid 351155828)
8. T Yoshinari M Matsumoto H Arakawa H Okada K Noguchi H Suda A Okura S Nishimura 1995 Novel antitumor indolocarbazole compound 6-N-formylamino-12,13- dihydro-1,11-dihydroxy-13-(beta-d-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c] carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity Cancer Res 55 1310 1315
9. T Yoshinari M Ohkubo K Fukasawa S Egashira Y Hara M Matsumoto K Nakai H Arakawa H Morishima S Nishimura 1999 Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I Cancer Res 59 4271 4275 (Pubitemid 29418742)
10. W Voigt U Vanhoefer MB Yin H Minderman HJ Schmoll YM Rustum 1997 Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines Anticancer Res 17 3707 3711 (Pubitemid 27522350)
11. H Arakawa M Morita T Kodera A Okura M Ohkubo H Morishima S Nishimura 1999 In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice Jpn J Cancer Res 90 1163 1170
12. H Komatani H Kotani Y Hara R Nakagawa M Matsumoto H Arakawa S Nishimura 2001 Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure Cancer Res 61 2827 2832 (Pubitemid 32691919)
13. RW Robey O Polgar J Deeken KW To SE Bates 2007 ABCG2: determining its relevance in clinical drug resistance Cancer Metastasis Rev 26 39 57 (Pubitemid 46452182)
14. LA Doyle DD Ross 2003 Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene 22 7340 7358 (Pubitemid 37487163)
15. Z Benderra AM Faussat L Sayada JY Perrot D Chaoui JP Marie O Legrand 2004 Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias Clin Cancer Res 10 7896 7902 (Pubitemid 39587528)
16. RW Robey Y Honjo A van de Laar K Miyake JT Regis T Litman SE Bates 2001 A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2) Biochim Biophys Acta 1512 171 182 (Pubitemid 32530764)
17. RW Robey WY Medina-Perez K Nishiyama T Lahusen K Miyake T Litman AM Senderowicz DD Ross SE Bates 2001 Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells Clin Cancer Res 7 145 152 (Pubitemid 32110217)
18. VK Rao D Wangsa RW Robey L Huff Y Honjo J Hung T Knutsen T Ried SE Bates 2005 Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells Cancer Genet Cytogenet 160 126 133 (Pubitemid 40910047)
19. RW Robey Y Honjo K Morisaki TA Nadjem S Runge M Risbood MS Poruchynsky SE Bates 2003 Mutations at amino acid 482 in the ABCG2 gene affect substrate and antagonist specificity Br J Cancer 89 1971 1978 (Pubitemid 37533279)
20. RW Robey K Steadman O Polgar K Morisaki M Blayney P Mistry SE Bates 2004 Pheophorbide a is a specific probe for ABCG2 function and inhibition Cancer Res 64 1242 1246 (Pubitemid 38235589)
21. O Polgar RW Robey K Morisaki M Dean C Michejda ZE Sauna SV Ambudkar N Tarasova SE Bates 2004 Mutational analysis of ABCG2: role of the GXXXG motif Biochemistry 43 9448 9456 (Pubitemid 38955477)
22. C Ozvegy-Laczka G Varady G Koblos O Ujhelly J Cervenak JD Schuetz BP Sorrentino GJ Koomen A Varadi K Nemet B Sarkadi 2005 Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface J Biol Chem 280 4219 4227 (Pubitemid 40288588)
23. P Skehan R Storeng D Scudiero A Monks J McMahon D Vistica JT Warren H Bokesch S Kenney MR Boyd 1990 New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 1107 1112 (Pubitemid 20213250)
24. W Chearwae S Anuchapreeda K Nandigama SV Ambudkar P Limtrakul 2004 Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder Biochem Pharmacol 68 2043 2052 (Pubitemid 39346194)
25. S Shukla RW Robey SE Bates SV Ambudkar 2006 The calcium channel blockers, 1, 4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2 Biochemistry 45 8940 8951 (Pubitemid 44100690)
26. SV Ambudkar 1998 Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells Methods Enzymol 292 504 514 (Pubitemid 29343911)
27. C Ozvegy T Litman G Szakacs Z Nagy S Bates A Varadi B Sarkadi 2001 Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells Biochem Biophys Res Commun 285 111 117 (Pubitemid 32912517)
28. KF Ejendal CA Hrycyna 2005 Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A Mol Pharmacol 67 902 911 (Pubitemid 40365337)
29. R Nakagawa Y Hara H Arakawa S Nishimura H Komatani 2002 ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport Biochem Biophys Res Commun 299 669 675 (Pubitemid 36034598)
30. LH Meng ZY Liao Y Pommier 2003 Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy Curr Top Med Chem 3 305 320
31. S Mizuarai N Aozasa H Kotani 2004 Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2 Int J Cancer 109 238 246 (Pubitemid 38240926)
32. Y Imai M Nakane K Kage S Tsukahara E Ishikawa T Tsuruo Y Miki Y Sugimoto 2002 C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141 K protein and low-level drug resistance Mol Cancer Ther 1 611 616
33. K Morisaki RW Robey C Ozvegy-Laczka Y Honjo O Polgar K Steadman B Sarkadi SE Bates 2005 Single nucleotide polymorphisms modify the transporter activity of ABCG2 Cancer Chemother Pharmacol 56 161 172 (Pubitemid 40884271)
34. A Sparreboom H Gelderblom S Marsh R Ahluwalia R Obach P Principe C Twelves J Verweij HL McLeod 2004 Diflomotecan pharmacokinetics in relation to ABCG2 421C > A genotype Clin Pharmacol Ther 76 38 44 (Pubitemid 38844732)
35. SE Bates WY Medina-Perez G Kohlhagen S Antony T Nadjem RW Robey Y Pommier 2004 ABCG2 mediates differential resistance to SN-38 and homocamptothecins J Pharmacol Exp Ther 310 836 842
36. FX Mahon F Belloc V Lagarde C Chollet F Moreau-Gaudry J Reiffers JM Goldman JV Melo 2003 MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models Blood 101 2368 2373 (Pubitemid 36304670)
37. C Brendel C Scharenberg M Dohse RW Robey SE Bates S Shukla SV Ambudkar Y Wang G Wennemuth A Burchert U Boudriot A Neubauer 2007 Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells Leukemia 21 1267 1275 (Pubitemid 46831816)